Filtered By:
Drug: Warfarin
Procedure: Hemodialysis

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 122 results found since Jan 2013.

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
This study simulated the dose-exposure relationship of dabigatran in patients undergoing haemodialysis. Dabigatran exposure was modelled at once- and twice-daily doses of 75 mg, 110 mg and 150 mg and at variations in non-renal clearance and dialysis settings. Resultant dose exposure (area under the curve [AUC]) was compared with values simulated from typical patients in the RE-LY® trial (based on a previously characterised pharmacometric model). In this simulation, all twice-daily dosages resulted in exposures above those simulated from typical RE-LY patients (1.5- to 3.3-fold increase in AUC) and thus may not be optimal ...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F Tags: Thromb Haemost Source Type: research

Peri-procedural management of patients taking oral anticoagulants
This article will help guide physician to better provide peri-procedural management of oral anticoagulation therapy. : Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation Update in Nephrology: Evidence Published in 2010 Policy Statement of Canadian Society of Transplantation and Canadian Society of Nephrology on Organ Trafficking and Transplant Tourism
Source: Nephrology Now - September 21, 2015 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: General Nephrology Review Source Type: research

Risk Factors of Ischemic Stroke and Subsequent Outcome in Patients Receiving Hemodialysis Clinical Sciences
Conclusions— Incidence of stroke is high in patients with ESRD on hemodialysis with high case-fatality. Incident hemodialysis patients had the highest stroke incidence. Many, but not all, important risk factors commonly associated with stroke in the general population were not associated with stroke in patients receiving hemodialysis.
Source: Stroke - August 24, 2015 Category: Neurology Authors: Findlay, M. D., Thomson, P. C., Fulton, R. L., Solbu, M. D., Jardine, A. G., Patel, R. K., Stevens, K. K., Geddes, C. C., Dawson, J., Mark, P. B. Tags: Cerebrovascular disease/stroke, Risk Factors for Stroke, Epidemiology Clinical Sciences Source Type: research

Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: A systematic review and a meta-analysis
Conclusion This meta-analysis suggested that warfarin should not be recommended for the routine treatment of HD patients with AF.
Source: Nutrition, Metabolism and Cardiovascular Diseases - July 20, 2015 Category: Nutrition Source Type: research

Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation
Conclusions In hemodialysis patients with incident AF, warfarin use was marginally associated with reduced risk of ischemic stroke, and there was a signal toward reduced mortality in as-treated analyses. These results support clinical equipoise regarding the use of warfarin in hemodialysis patients and underscore the need for randomized trials to fill this evidence gap.
Source: American Journal of Kidney Diseases - July 9, 2015 Category: Urology & Nephrology Source Type: research

Reply: Warfarin in patients on haemodialysis with atrial fibrillation—friend or foe?
Nature Reviews Nephrology 11, 450 (2015). doi:10.1038/nrneph.2015.103 Authors: Arman Qamar & Deepak L. Bhatt We would like to thank G. Schlieper and J. Floege for their comments on our News & Views article (Anticoagulation therapy: Balancing the risks of stroke and bleeding in CKD. Nat. Rev. Nephrol.11, 200–202; 2015), in which relevant concerns pertaining
Source: Nature Reviews Nephrology - July 7, 2015 Category: Urology & Nephrology Authors: Arman QamarDeepak L. Bhatt Tags: Reply Source Type: research

Warfarin for stroke prevention in hemodialysis patients with non-valvular atrial fibrillation.
PMID: 26882633 [PubMed - in process]
Source: CANNT Journal - July 1, 2015 Category: Urology & Nephrology Authors: Badr S, Cameron K, Battistella M Tags: CANNT J Source Type: research

IMAGES IN CLINICAL MEDICINE Lindsay ’s Nails in Chronic Kidney Disease
This image says it all.  An interesting nail bed finding in CKD. : Intestinal radiopacities in chronic renal failure Case Records of the Massachusetts General Hospital. Case 35-2015: A 72-Year-Old Woman with Proteinuria and a Kidney Mass. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation
Source: Nephrology Now - May 8, 2015 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Chronic Kidney Disease Clinical Nephrology Source Type: research

IMAGES IN CLINICAL MEDICINE Lindsay’s Nails in Chronic Kidney Disease
This image says it all.  An interesting nail bed finding in CKD. : Intestinal radiopacities in chronic renal failure Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation Use of phosphate-binding agents is associated with a lower risk of mortality
Source: Nephrology Now - May 8, 2015 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Chronic Kidney Disease Clinical Nephrology Source Type: research

The Risks of Stroke and Bleeding for Warfarin Use in Hemodialysis Patients with Atrial Fibrillation: A Systemic Review and A Meta-Analysis
Conclusion This meta-analysis suggested that warfarin should not be recommended for the routine treatment of HD patients with AF.
Source: Nutrition, Metabolism and Cardiovascular Diseases - April 3, 2015 Category: Nutrition Source Type: research

Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: A systematic review and a meta-analysis
The efficacy and safety of warfarin therapy in hemodialysis (HD) patients with atrial fibrillation (AF) remains controversial. Thus, we performed, up to date, the first meta-analysis on the risks of stroke and bleeding in warfarin treatment in these populations.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - March 31, 2015 Category: Nutrition Authors: Jingzhen Li, Lijuan Wang, Jinzhu Hu, Gaosi Xu Tags: Systematic review Source Type: research

The Risks of Stroke and Bleeding for Warfarin Use in Hemodialysis Patients with Atrial Fibrillation: A Systemic Review and A Meta-Analysis
The efficacy and safety of warfarin therapy in hemodialysis (HD) patients with fibrillation (AF) remains controversial. Thus, we performed up to date, the first meta-analysis about the risks of stroke and bleeding of warfarin treatment in these populations.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - March 31, 2015 Category: Nutrition Authors: Jingzhen Li, Lijuan Wang, Jinzhu Hu, Gaosi Xu Source Type: research

Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation
This interesting study of hemodialysis patients on oral anticoagulation for atrial fibrillation showed that although their overall mortality was high – it was not associated with warfarin.  In fact, warfarin was associated with better survival and antiplatelet agents increased overall mortality. . : The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis Stroke and Bleeding in Atrial Fib...
Source: Nephrology Now - March 18, 2015 Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Clinical Nephrology Hemodialysis Source Type: research

Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man
Dabigatran is an oral direct inhibitor indicated for stroke prevention in patients with atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that laboratory test and dose adjustments are not necessary; nevertheless, circumstances of excessive anticoagulation, decreased kidney function, and instances of significant bleeding and thrombosis require laboratory assessment. In order to gather experience in the management of global [activated partial thromboplastin time (APTT) and thrombin time (TT) with extended endpoint] and specific [ecarin chromogenic assa...
Source: Blood Coagulation and Fibrinolysis - January 30, 2015 Category: Hematology Tags: Case Reports Source Type: research